SavedAdd your journal

Journals / GORM:Gynecology Obstetrics & Reproductive Medicine / 2005 / Cilt: 11 - Sayı: 2

Effects of postmenopausal use of raloxifene on serum homocysteine and lipid profile

Deniz KÖSE
Hüsamettin USLU
Özay ORAL
Semih TUĞRUL
Akif ALKAN
Evrim AKSOY
Pages
117–119
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Raloxifene can be used safely in postmenopausal patients regarding lipid profile.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate the effects of Raloxifene in postmenopausal patients on serum homocysteine levels and lipid profile.
📊
Key Findings & Data:Study Design: 51 patients who had been followed prospectively were included in this study.
💡
Conclusion & Impact:Raloxifene can be used safely in postmenopausal patients regarding lipid profile.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Lipoproteinler · LDL · Lipoproteinler

Abstract

Objective: To evaluate the effects of Raloxifene in postmenopausal patients on serum homocysteine levels and lipid profile. Study Design: 51 patients who had been followed prospectively were included in this study. All the patients were given 60 mg Raloxifene single dose daily for 6 months. Pre-treatment and 6th month serum levels had been recorded evaluating homocysteine, total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL) and triglyceride levels. Statistical analysis was made by using paired t-test on SPSS version 11.5. Results: Mean patient age was 54.1±6.7 years and mean menopause age was 7.1±5.7 years. No significant differences were recorded in terms of serum homocysteine, HDL and triglyceride levels in the pre and post treatment groups. Significant decrease was recorded in the 6th month serum levels of total cholesterol and LDL levels compared to pre-treatment levels. (p<0.05, p<0.001 respectively) Conclusion: The levels of homocysteine have not been altered after 6 months of Raloxifene use and we have found a significant decrease in total cholesterol and LDL levels. Raloxifene can be used safely in postmenopausal patients regarding lipid profile.

🔖

Cite This Article

KÖSE, D., USLU, H., ORAL, Ö., TUĞRUL, S., ALKAN, A., AKSOY, E. (2005). Effects of postmenopausal use of raloxifene on serum homocysteine and lipid profile. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 11 - Sayı: 2, 117–119. https://ajindex.com/articles/227571

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Mosca L, Manşon "JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women. Circulation. 1997
  2. Pines A, Mijatovic V, van der Mooren MJ, Kenemans P. Hormone replacement therapy and cardioprotection:basic concepts and clinical considerations. Eur J Obstet Gynecol Reprod Biol. 1997
  3. Col NF, Eckman MH, Karas RH, Pauker SG, Goldberg RJ, Ross EM, Orr RK, Wong JB. Patient-spesific decisions­ about hormone replacement therapy in postmenopausal women. JAMA. 1997
  4. Kauffman RF, Bryant HU. Selective Estrogen Receptor Modulators. DN&P 1995
  5. Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med. 1999
  6. Boushey CJ, Beresford SA, Omenn GS, MotulskyAG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease.Probable benefits of increa­sing folic acid intakes. JAMA. 1995
  7. den Heijer M, Blom HJ, Gerrits WB, Rosendaal FR, Haak HL, Wijermans PW, Bos GM. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis? Lancet. 1995
  8. Wouters MG, Moorrees MT, van der Mooren MJ, Blom HJ, Boers GH, Schellekens LA, Thomas CM, Eskes TK. Plasma homocysteine and menopausal status. Eur J Clin Invest. 1995
  9. Harpel PC, Zhang X, Borth W. Homocysteine and hemostatis: pathogenic mechanisms predisposing to thrombosis. J Nutr. 1996
  10. 126(4 Suppl): 1285-9. 10.Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and throm­bosis. Thromb Res. 1993
  11. Mijatovic V, Kenemans P, Jakobs C, Van Baal WM, Peters-Muller ER, van der Mooren MJ. A randomized con­trolled study of the effects of 17 Beta-Estradiol-Dydrogesterone on plasma homocysteine in postmenopausal women. Obstet Gynecol. 1998
  12. Mijatovic V, Netelenbos C, van der Mooren MJ, de Valk-de Roo GW, Jakobs C, Kenemans P. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril. 1998
  13. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation. 1997
  14. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC. Raloxifene (LY139481 HCL) prevents bone loss and reduces serum cholesterol without causing